Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Nurix Therapeutics, Inc. (NRIX) had Return on Investments of -22.24% for the most recently reported fiscal quarter, ending 2026-05-31.
| Income Statement Financials | |
$9.04M |
|
$-89.53M |
|
-- |
|
$9.04M |
|
$103.25M |
|
$-94.20M |
|
$4.40M |
|
$-89.81M |
|
$-89.81M |
|
$-89.53M |
|
$-89.53M |
|
$-89.53M |
|
$-89.53M |
|
$-94.20M |
|
$-90.35M |
|
111.08M |
|
111.08M |
|
$-0.81 |
|
$-0.81 |
|
| Balance Sheet Financials | |
$456.48M |
|
$20.01M |
|
$79.06M |
|
$535.54M |
|
$72.02M |
|
-- |
|
$60.89M |
|
$132.91M |
|
$402.63M |
|
$402.63M |
|
$402.63M |
|
103.70M |
|
| Cash Flow Statement Financials | |
$-168.49M |
|
$-30.83M |
|
$20.04M |
|
$247.93M |
|
$68.65M |
|
$-179.28M |
|
$20.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1041.73% |
|
-1041.73% |
|
-- |
|
-993.10% |
|
-990.10% |
|
$-171.47M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-22.24% |
|
-22.24% |
|
-16.72% |
|
|
Return on Investments |
-22.24% |
$3.88 |
|
$-1.54 |
|
$-1.52 |
|